353 related articles for article (PubMed ID: 23574779)
1. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
4. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
5. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
Dvorácková J; Uvírová M
Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
[TBL] [Abstract][Full Text] [Related]
6. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
7. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
8. Genetic profile identification in clinically localized prostate carcinoma.
Gallucci M; Merola R; Leonardo C; De Carli P; Farsetti A; Sentinelli S; Sperduti I; Mottolese M; Carlini P; Vico E; Simone G; Cianciulli A
Urol Oncol; 2009; 27(5):502-8. PubMed ID: 18534873
[TBL] [Abstract][Full Text] [Related]
9. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
10. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy.
Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O
Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
12. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
[TBL] [Abstract][Full Text] [Related]
13. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
14. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
15. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA; Zafarana G; Ishkanian AS; Milosevic M; Thoms J; Have CL; Malloff CA; Lam WL; Squire JA; Pintilie M; Sykes J; Ramnarine VR; Meng A; Ahmed O; Jurisica I; van der Kwast T; Bristow RG
Clin Cancer Res; 2012 Jan; 18(1):308-16. PubMed ID: 22048240
[TBL] [Abstract][Full Text] [Related]
16. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.
Qian J; Jenkins RB; Bostwick DG
Mod Pathol; 1997 Nov; 10(11):1113-9. PubMed ID: 9388062
[TBL] [Abstract][Full Text] [Related]
17. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
19. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
20. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
